ProMIS Neurosciences, Inc. (PMN)
Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High?
The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 230.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy
Promis Neurosciences (PMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 231.8% in Promis Neurosciences (PMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Ally Bridge Group NY LLC Increases Holdings in Promis Neurosciences $PMN
Ally Bridge Group NY LLC increased its position in Promis Neurosciences (NASDAQ: PMN) by 367.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,233,497 shares of the company's stock after buying an additional 4,899,069 shares during the quarter. Promis Neurosciences
